Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company is dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (e.g. monoclonal antibodies, growth factors, enzymes). The Company’s SUREtechnology Platform™ offers comprehensive and rapid solutions for the development of stable and high yield mammalian cell lines. For over 10 years, Selexis has built interactive collaborations, partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide. From discovery to Phase II clinical trials, Selexis’ technology has been and is currently being used by more than 50 companies worldwide.
BioXpress Therapeutics
Located in Geneva, Switzerland, BioXpress Therapeutics SA (BXT) is a premier provider of high-quality biosimilar monoclonal antibody (MAbs) for unmet need indications. As a class, MAbs are forecasted to grow at a CAGR approaching 10% over the next five years, driven largely by positive results in the clinic. Cancers and immune-related inflammatory diseases will continue to be leading markets for MAbs during the next five-years.
BXT is focused on developing the highest quality product under strict European Medicines Agency (EMA) guidelines. We bring together the world’s top biologic development, manufacturing and regulatory experts dedicated to assuring the quality of our drugs. BXT believes all patients should have access to safe and high-quality biologic therapeutics at affordable costs.